• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.360 +0.020 (+0.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,916,142
Open 5.290
Bid (Size) 5.370 (100)
Ask (Size) 5.450 (600)
Prev. Close 5.340
Today's Range 5.060 - 5.550
52wk Range 1.100 - 10.08
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here are the top movers in Thursday's session. ↗
January 08, 2026
Via Chartmill
These stocks are gapping in today's session ↗
January 08, 2026
Via Chartmill

Performance

YTD
-19.0%
-19.0%
1 Month
-20.4%
-20.4%
3 Month
-14.9%
-14.9%
6 Month
+37.1%
+37.1%
1 Year
+182.1%
+182.1%

More News

Read More
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
January 08, 2026
Via Chartmill
IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
January 07, 2026
Via Stocktwits
Stay updated with the stocks that are on the move in today's after-hours session. ↗
January 07, 2026
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
November 12, 2025
Via Benzinga
Why Immuneering Stock Soared Over 40% After-Hours Today ↗
September 24, 2025
Via Stocktwits
News headline image
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
January 07, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
December 23, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
December 17, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
December 16, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
Immuneering (IMRX) Q3 2025 Earnings Transcript ↗
November 13, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
November 12, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
A Preview Of Immuneering's Earnings ↗
November 11, 2025
Via Benzinga
News headline image
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
November 04, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
September 27, 2025
Via MarketMinute
News headline image
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
September 26, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
September 25, 2025
Via Benzinga
News headline image
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗
September 25, 2025
Via Benzinga
News headline image
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
September 25, 2025
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
September 24, 2025
Via Benzinga
News headline image
Top movers in Wednesday's after hours session ↗
September 24, 2025
Via Chartmill

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 5.360
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 01/23/26 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 139.03M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 139M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap